The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M. Ryckman, Bradley N. Reames, Kelsey A. Klute, William A. Hall, Michael J. Baine, May Abdel-Wahab, Chi Lin

Research output: Contribution to journalReview articlepeer-review

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

Original languageEnglish (US)
Pages (from-to)124-128
Number of pages5
JournalClinical and Translational Radiation Oncology
Volume28
DOIs
StatePublished - May 2021

Keywords

  • Pancreatic cancer
  • Stereotactic body radiotherapy
  • Total neoadjuvant therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?'. Together they form a unique fingerprint.

Cite this